Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice.
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Clinically feasible MTR is sensitive to cortical demyelination in MS.
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Treatment of neurological injury with thymosin β4.
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Rituximab and multiple sclerosis.
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.

Pages